Applying Patient-Centered Management Strategies to Immune Thrombocytopenia: Allison Miller Imahiyerobo, APN

Immune thrombocytopenia (ITP) is an acquired immune-mediated disorder defined as a peripheral blood platelet count <100 x 109/L with no known cause. In this excerpt of the transcript from her nursing continuing professional development (NCPD)–approved activity, Immune Thrombocytopenia: Evolving Treatment Paradigms and Patient-Centered Care, Allison Miller Imahiyerobo, APN, an advanced practice nurse at the Hematology and Oncology Physicians of Englewood, discusses the pathogenesis of ITP, eme...
Continue reading

Sacituzumab Govitecan for Advanced Urothelial Cancer: Petros Grivas, MD, PhD

Recently, the FDA granted accelerated approval to sacituzumab govitecan (Trodelvy®, Immunomedics), an antibody-drug conjugate, for patients with locally advanced or metastatic urothelial cancer whose disease progressed following treatment with platinum-containing chemotherapy and a programmed cell death protein 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor. In this interview with Oncology Data Advisor, Dr. Petros Grivas, Associate Professor and Clinical Director of the Genitourinary Cance...
Continue reading

Camrelizumab for Advanced Squamous Non-Small Cell Lung Carcinoma: Caicun Zhou, MD, PhD

Recently, the results of a phase 3 trial on camrelizumab were published in the Journal of Thoracic Oncology and presented at the European Lung Cancer Virtual Congress 2021. Camrelizumab was studied in the randomized, double-blind, multicenter trial as a treatment for advanced squamous non-small cell lung carcinoma (NSCLC). Patients with stages IIIB-IV squamous NSCLC were treated with carboplatin plus paclitaxel with camrelizumab or placebo in the first-line setting. Compared with those who recei...
Continue reading

Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Nina Shah, MD

Recently, the FDA approved idecabtagene vicleucel (Abecma®, Bristol Myers Squibb) for patients with relapsed or refractory multiple myeloma who have already been treated with four or more lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. The approval was based on KarMMa, a phase 2 trial that confirmed the efficacy and safety of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma. In this interview, one of...
Continue reading

Sacituzumab Govitecan for Triple-Negative Breast Cancer: Aditya Bardia, MD

Recently, the FDA granted regular approval to sacituzumab govitecan (Trodelvy®, Immunomedics, Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have previously been treated with two or more systemic therapies, at least one of them for metastatic disease. The FDA had previously granted accelerated approval to sacituzumab govitecan based on the results of the phase 1/2 IMMU-132-01 study (NCT01631552); the phase 3 ASCENT study (NCT02574455)...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.